The researchers found that IAs alone, tTGAs alone, and both appeared in 367, 808, and 90 children, respectively, with co-occurrence significantly exceeding the expected rate.
Compared with injection therapy, pump therapy was correlated with lower rates of severe hypoglycemia (9.55 versus 13.97 per 100 patient-years) and diabetic ketoacidosis (3.64 versus 4.26 per 100 patient-years).
Study authors explained that using antibacterial mouthwash can eradicate oral microbes needed for nitric oxide formation and place the user at risk for metabolic disorders.
Specifically, the key highlights of the label update include new study data that describe the time-action profile by dosage strength of Afrezza as well as clarity on "starting" and "adjusting" mealtime dose.
A trial (Dunn T et al. 2017) of ≥50,000 diabetes patients, that lasted 18 months, found that FreeStyle Libre users checked their glucose on average 16 times a day.
Significant improvement in IGF-II serum levels were found with liraglutide for obese with prediabetes, early T2DM
An additional second-line antihyperglycemic medication or insulin was more likely in patients given their initial second-line medication without evidence of recommended use of metformin (P<0.001).
Researchers aimed to determine whether the rise in prescription drug use over time varied by age and obesity status.
The researchers found that the adjusted mean changes from baseline in body weight in the surgery group were −45.0, −36.3, and −35.0 kg at 2, 6, and 12 years, respectively.
Humalog Junior KwikPen U-100 will be available as 5-count cartons. The BD pen needles are recommended for use with Humalog Junior KwiKPen.
The researchers found that there was no significant difference in percent change in LDL-C level between the 2 groups at 24 weeks.
Patients with type 2 diabetes who experience severe hypoglycemia may be at an increased risk of death following the episode.
The patches mechanism of action turns white adipose tissue into brown adipose tissue, white tissue is known to store fat while brown tissue is known to burn fat to produce heat.
Study authors analyzed the occurrence of amputation in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors vs. non-SGLT2 inhibitors, and specifically, canagliflozin.
Compared to placebo, Repatha was not associated with an increased risk of developing new-onset diabetes or worsening glycemia over a median follow-up period of 2.2 years in patients without diabetes at baseline.
The researchers found that 11.4% of patients in the exenatide group and 12.2% in the placebo group had a primary composite event (hazard ratio, 0.91; 95% confidence interval, 0.83 to 1.00); in the intention-to-treat analysis.
Compared with women who did not consume caffeine, women who consumed caffeine had an adjusted hazard ratio for death of 0.49 for <100 mg caffeine/day, 0.43 for 100 to <200mg/day, and 0.34 for ≥200 mg caffeine/day (P=0.007).
The researchers found that the proportion of patients achieving the primary end point (glycated hemoglobin level <7.0% at week 24, with no episodes of severe hypoglycemia or diabetic ketoacidosis) was significantly larger in the sotagliflozin versus the placebo group.
The difference was greater in obese subjects, and declined to normal following BPD. No evidence was found for glucose malabsorption.
The data came from a post-hoc analysis of two randomized-controlled trials that compared Xultophy to insulin degludec (DUAL II) and to insulin glargine U100 (DUAL V).
During the study period (4.6 years) 12.1% of placebo group participants primary endpoint compared to 10.4% (Empagliflozin 10mg) and 10.5% (Empagliflozin 25mg) (P<0.0001).
The researchers found in an eGFR trajectory analysis that 10.1% of participants were rapid decliners, with a mean decrease of 2.9 mL/min/1.73 m²/year.
Pending any patent issues that have yet to be resolved by the Company, the FDA has concluded that the product has met all necessary regulatory requirements for approval.